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Aims: 
   Incidence rates of gastro-oesophageal adenocarcinomas are rising and despite 
many tumours being detected at a locally advanced stage outcomes following 
surgical resection remain poor. The MRC STO2 (MAGIC) trial demonstrated a 
13% improvement in 5 year survival with perioperative chemotherapy followed by 
surgery in resectable gastro-oesophageal adenocarcinomas. We sought to 
assess treatment delivery, survival outcomes and prognostic factors for 
oesophago-gastric adenocarcinoma patients treated with peri-operative 
chemotherapy at a regional tertiary referral centre. 
 
Methods: 
   Planned chemotherapy comprised of 3 cycles of preoperative and 3 cycles of 
postoperative ECF/X (Epirubicin 50mg/m2 D1, cisplatin 60mg/m2 D1 and 5-
fluorouracil 200mg/m2/day/Capecitabine 625mg/m2/day). Pathological response 
to treatment was reviewed and graded by an individual pathologist for 
consistency. Baseline demographics, treatment details and clinical outcomes 
were collected and clinical and pathological factors predicting outcome were 
assessed. 
 
Results: 
   From January 2004 to December 2012, 183 patients with oesophageal and 
GOJ adenocarcinoma were treated with peri-operative chemotherapy. Patients at 
our centre were significantly older (p=0.021) and had a poorer performance 
status (p<0.0001) compared to the MAGIC trial.  The median age was 64 years 
(range 28-83) and 70% of patients were ECOG performance status 1/2. 177 
(96.7%) of patients proceeded to planned surgical resection with 58.5% and 
43.7% commencing and completing post-operative chemotherapy, respectively. 
The median overall survival (OS) was 38.8 months with a 5 year OS of 37.9%, 
compared to 36% in the MAGIC trial.  Pathological response, clear 
circumferential margin and absence of lymphovascular invasion were statistically 
significant predictors of both relapse free and overall survival. 
   
Conclusions: 
   Despite an older and poorer performance status population, treatment delivery 
and survival outcomes for operable gastro-oesophageal adenocarcinoma at our 
centre were better than the published data. Predictive biomarkers are needed to 
individualise systemic therapy and there is renewed interest in the role of 
neoadjuvant chemoradiotherapy to improve complete resection rates. 
 
 
